Lipoxygenases in chronic liver diseases: current insights and future perspectives

Lena Heinrich; Richell Booijink; Amit Khurana; Ralf Weiskirchen; Ruchi Bansal

doi:10.1016/j.tips.2021.12.001

Lipoxygenases in chronic liver diseases: current insights and future perspectives

Trends Pharmacol Sci. 2022 Mar;43(3):188-205. doi: 10.1016/j.tips.2021.12.001. Epub 2021 Dec 24.

Authors

Lena Heinrich¹, Richell Booijink¹, Amit Khurana², Ralf Weiskirchen³, Ruchi Bansal⁴

Affiliations

¹ Translational Liver Research, Department of Medical Cell BioPhysics, Faculty of Science and Technology, Technical Medical Center, University of Twente, Enschede 7500 AE, The Netherlands.
² Translational Liver Research, Department of Medical Cell BioPhysics, Faculty of Science and Technology, Technical Medical Center, University of Twente, Enschede 7500 AE, The Netherlands; Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), Rheinisch-Westfälische Technische Hochschule (RWTH) University Hospital Aachen, Aachen 52074, Germany; Centre for Biomedical Engineering (CBME), Indian Institute of Technology (IIT), Hauz Khas, New Delhi 110016, India.
³ Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), Rheinisch-Westfälische Technische Hochschule (RWTH) University Hospital Aachen, Aachen 52074, Germany.
⁴ Translational Liver Research, Department of Medical Cell BioPhysics, Faculty of Science and Technology, Technical Medical Center, University of Twente, Enschede 7500 AE, The Netherlands. Electronic address: r.bansal@utwente.nl.

PMID: 34961619
DOI: 10.1016/j.tips.2021.12.001

Abstract

Chronic liver diseases (CLDs) caused by viral infections, alcohol/drug abuse, or metabolic disorders affect millions of people globally and have increased mortality owing to the lack of approved therapies. Lipoxygenases (LOXs) are a family of multifaceted enzymes that are responsible for the oxidation of polyunsaturated fatty acids (PUFAs) and are implicated in the pathogenesis of multiple disorders including liver diseases. This review describes the three main LOX signaling pathways - 5-, 12-, and 15-LOX - and their involvement in CLDs. We also provide recent insights and future perspectives on LOX-related hepatic pathophysiology, and discuss the potential of LOXs and LOX-derived metabolites as diagnostic biomarkers and therapeutic targets in CLDs.

Keywords: biomarkers; chronic liver diseases; lipoxygenase metabolites; lipoxygenases; specialized proresolving mediators; therapeutics.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Fatty Acids, Unsaturated
Humans
Lipoxygenases / metabolism
Liver Diseases*
Metabolic Diseases*
Oxidation-Reduction

Substances

Fatty Acids, Unsaturated
Lipoxygenases